Sign In
Last checked at 
23 Apr 2026 15:00
RNS Number : 7133B
Reckitt Benckiser Group PLC
23 April 2026
23 April 2026
RECKITT BENCKISER GROUP PLC
Director Declaration
Reckitt Benckiser Group plc ('Reckitt') announces that Harry Kirsch, a Non-Executive Director for Reckitt, has been appointed as a Director on the Board of Galderma (SIX: GALD), from 22 April 2026.
This notification is made in accordance with Listing Rule 9.6.14 of the FCA's Listing Rules.
CONTACT DETAILS:
Contacts
Nick Ashworth +44 (0) 7408 812350
SVP Investor Relations
Catheryn O'Rourke +44 (0) 1753 217 800
General Counsel & Company Secretary
About Reckitt:
We make the products people trust to care for the ones they love. We are home to some of the world's best-loved consumer health and hygiene brands, including Dettol, Durex, Finish, Gaviscon, Harpic, Lysol, Mucinex, Nurofen, Strepsils, Vanish and Veet. Consumers are at the heart of everything we do. By creating innovative, science-backed solutions, we support people every day to live healthier lives.
Reckitt exists to protect, heal and nurture in the pursuit of a cleaner, healthier world. This commitment goes beyond the products we make. Through our actions, we expand access to healthcare, education and economic opportunities. We support the planet by reducing waste, conserving resources and driving sustainable innovation.
We believe good health starts at home. With every action we take, we strive to make our consumers' lives easier, cleaner and healthier, to strengthen communities and to create a more sustainable future.
Find out more or get in touch with us at www.reckitt.com.
*Reckitt is the trading name of the Reckitt Benckiser group of companies
Reckitt Benckiser Group plc's LEI code is 5493003JFSMOJG48V108
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Follow the stocks
